Sunday, January 10, 2016 7:22:00 PM
Ready, I like to hear all arguments, no matter how far out there, as long as the poster makes the effort to present his or her opinion and back it up with some thought and/or research. Then I put everything on the table and make my own best judgment on how to invest my money. But we need to hear all sides in order to make that informed decision.
To be honest, I think we have a lot of information about this treatment. We have seen it work in the information arm,we've heard comments from doctors involved in the process, we have regulatory bodies in Germany and the UK lining up behind NWBO with early approvals. The question now is will the placebo come in at some outrageously long PFS, so that L can't get the magic 4 months of PFS it needs to get to approval. Frankly, I think it will get it but even if it doesn't, I think it is likely to be approved for certain gene types or groups.
We can stick our heads in the sand and wait for some regulatory body to reveal what's going on, or we can keep debating and gather more opinions/informations/data....whatever you want to call it...in order to make more informed decisions.
To be honest, I think we have a lot of information about this treatment. We have seen it work in the information arm,we've heard comments from doctors involved in the process, we have regulatory bodies in Germany and the UK lining up behind NWBO with early approvals. The question now is will the placebo come in at some outrageously long PFS, so that L can't get the magic 4 months of PFS it needs to get to approval. Frankly, I think it will get it but even if it doesn't, I think it is likely to be approved for certain gene types or groups.
We can stick our heads in the sand and wait for some regulatory body to reveal what's going on, or we can keep debating and gather more opinions/informations/data....whatever you want to call it...in order to make more informed decisions.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
